Author:
Skripka A I,Kogay V V,Listratov A I,Sokolova A A,Napalkov D A,Fomin V V
Abstract
Data on possibilities of personalized approach for direct oral anticoagulants (DOAC) choice in patients with atrial fibrillation are presented in the article. We also review clinical and fundamental studies and future perspectives on pharmacogenetic and pharmacokinetic tests to predict the efficacy and safety of DOAC.
Subject
General Medicine,Endocrinology, Diabetes and Metabolism,History,Family Practice
Reference62 articles.
1. Сычев Д.А., Игнатьев И.В., Емельянов Н.В., Савельева М.И., Дмитриев В.А., Кукес В.Г., Герасимова К.В. Фармакогенетическое тестирование: первые шаги в реальной клинической практике и проблемы стандартизации. Проблемы стандартизации в здравоохранении. 2009;1:43-55.
2. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
3. Инструкция по применению лекарственного препарата Прадакса. Государственный реестр лекарственных средств. Доступно по: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=e4817690-bf14-4e4e-9562-256d415636c7&t=. Ссылка активна на 25.10.2018.
4. The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients
5. Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献